MedTrace Logo

Characterizing Response to Antipsychotics in Schizophrenia

NCT06159322 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-12-06

No results posted yet for this study

Summary

The goal of this research project is to develop MRI-based biomarkers to identify patients with schizophrenia who are most likely to benefit from first-line antipsychotic or clozapine treatment. The MRI sequences (NM-MRI, MRS and rsfMRI) will be created by translating the best scientific evidence into a potential clinical product that has the highest chance of being clinically relevant predictor of treatment response. This study has the potential to significantly improve patient outcomes and reduce unnecessary interventions and costs at the Royal's Integrated Schizophrenia Recovery Program.

Conditions

Interventions

DRUG

Olanzapine

Antipsychotic medication

DRUG

Clozapine

Antipsychotic medication

Sponsors & Collaborators

  • The Royal's Institute of Mental Health Research

    collaborator OTHER

  • The Royal Ottawa Mental Health Centre

    lead OTHER

Principal Investigators

  • Lauri Tuominen, MD, PhD · The Royal's Institute of Mental Health Research

  • Clifford Cassidy, PhD · The Royal's Institute of Mental Health Research

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-01-30
Completion
2024-01-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06159322 on ClinicalTrials.gov